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Theauthorhypothesizedthatmultiplesclerosis(MS)isahumoralautoimmunedisease,causedbyfaultyinterplaybetweenmyelin-
speciﬁc,dimericIgE,speciﬁcally competingnon-IgEantibodiesandIgE-triggereddegranulatingmastcells.Theprincipalfaultwas
believedtobeinsuﬃcientquantityofprotective,speciﬁcnon-IgEantibodies.Alsoconjecturedwasthepossibilityofanunexpected
and adverse immune suppression caused by none-MS pharmaceuticals being consumed by patients for their MS or for other
conditions. To test both hypotheses, a mimotopic, peptide antigen-based, serum immunoassay was developed to measure dimer-
bound IgE excess among MS patients, wherein the IgE speciﬁcally complexes with two or more myelin surface epitopes at an
interval of 40–100 Angstroms, a separation critical for mast cell degranulation and cell damaging eﬀect. MS test sensitivity and
speciﬁcity, when analyzing ﬁve previously untreated patients for dimeric IgE presence, was 100%. In direct comparison, twenty
age- and gender-matched female and male control subjects were test negative. Analysis of 35 multiple sclerosis patients, who were
concomitantly being treated with potentially immunosuppressive pharmaceuticals, appeared to show the substances’ negative
eﬀect upon MS causation, progression, or speciﬁc immunoassay performance. Therefore, MS is likely an autoimmune disease
caused by IgE-mediated mast cell degranulation possibly in conjunction with immunosuppressive agents.
1.Introduction
While it is commonly understood that multiple sclerosis
(MS)isanautoimmunediseaseofmultifactorialetiology,the
exact mechanism of causation has not yet been elucidated.
Consequently, disease-speciﬁc MS therapy has not advanced
beyond the use of interferons and immunosuppressive
agents,theapplicationofwhichis now morethanthirty-year
old [1, 2] and of questionable, long-term eﬃcacy [3].
Based upon his early work [4] and the work of other
investigators [5–11], the author hypothesized that MS is
a humoral autoimmune disease, caused by faulty interplay
between myelin-speciﬁc IgE, competing speciﬁc non-IgE
antibodies, and IgE-triggered, degranulating mast cells. Af-
fected mast cells are likely to expel proteolytic enzymes and
possibly other factors which damage or destroy targeted
myelin and the axons that are sheathed by it.
To test the hypothesis, a mimotopic, peptide antigen-
based, serum immunoassay was developed to measure
dimer-bound IgE excess among MS patients, wherein the IgE
speciﬁcally complexes with two or more myelin surface
epitopes at an interval of 40−100 ˚ Angstr¨ oms, a separation
critical for mast cell degranulation [12] and tissue-damaging
eﬀect.
Because MS patients often consume numerous medica-
tions, some started before observed disease onset, questions
arise about the medications’ eﬀect upon (1) disease origin,
(2) serum antibody test function, and (3) hindrance of nor-
mal and protective, humoral immune processes.
Epitope-speciﬁc IgE is but one isotype involved in the
myelin inﬂammatory process as other investigators have
also documented the presence of myelin-speciﬁc IgA, IgG,
and IgM [13]. Concomitantly present, the diﬀering isotypes
are likely to be cross-competitive for epitopic antigens. An
analytical method was therefore developed to measure this
potential competition and a determination made whether
the competition exists and is likely part of the MS autoim-
mune process.
The analytical method entailed quantiﬁcation of the
ratio of myelin epitope-speciﬁc IgE relative to the sum of2 ISRN Neurology
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Figure 2: A schematic illustration of myelin proteolipid protein Isoform 1 is shown. Depicted are: (a) amino acid sequence portions
that are net hydrophilic and located on the myelin protein (oligodendrocyte) surface (blue-green highlight); (b) portions that are net
hydrophobic and project inwardly within the myelin glycolipid layer (uncolored); and (c) portions that are hydrophilic and intracellular
(yellow highlighted).
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Figure 3: A schematic drawing is shown wherein the location of a myelin-speciﬁc epitope, ADARM, is illustrated by performing a pictorially
functional readjustment of Figure 1(a), removing rows 1–38, 48-49, 50–116, 155–188, 198-199, and 209–277 to visualize the 3 hydrophilic
surfaceplatforms,susceptibletoautoantibodybinding.Theindividualplatformsencompassaminoacidsnumber39−49,189–197,and200–
208.Twointracellular,hydrophilicplatformsencompassaminoacidsnumber,117–141and145–154.Theunique,correspondingaminoacid
hydrophilic indices, −0.5, 3, −0.5, 3, and −1.3 depicted in column 6.6 ISRN Neurology
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Figure 4: Displayed is the measured distance between two IgE autoantibodies if each was to bind a potential epitopic dimer site (QAPEY
and VTLRI) with each site incorporating ﬁve, uniquely sequenced, contiguous amino acids ﬂanked on either end by a nonreactive, normally
present amino acid thus making a 7 amino acid, antibody binding footprint. Each intervening amino acid between epitopes is estimated to
be 10.6 ˚ Angstr¨ oms in width. When the interfootprint dimer distance analysis is performed, the potential dimer between QAPEY and VTLRI
is inadequate for mast cell degranulation because there are 13 intervening amino acids between the two epitopes, and this is equivalent to a
distance of 103 ˚ Angstr¨ oms, which is 3 ˚ Angstr¨ oms above the mandated upper limit of 100 ˚ Angstr¨ oms. HI: peptide hydrophilic index.ISRN Neurology 7
Table 1: Illustrated is the method employed in estimating the average diameter, in ˚ Angstr¨ oms, of the twenty standard amino acids. The
method entails (1) estimating the nanometers diameter of each non-alanine amino acid relative to the known diameter of alanine, 0.69
nanometer, using the formula, amino acid molar mass/alanine molar mass ×0.69 nanometer(s); (2) multiplying each estimated amino acid
diameter times 10 in order to convert each amino acid diameter from nanometers to ˚ Angstr¨ oms; (3) summing the ˚ Angstr¨ oms diameters and
dividing by 20 to yield an average amino acid diameter per amino acid equal to 10.6 ˚ Angstr¨ oms.
Estimation of average amino acid diameter
Molar mass Amino acids Nanometer diameter Diameter in ˚ Angstr¨ oms
89.1 A Alanine 0.6∗∗ 6.9
132.1 N Asparagine 1.02 10.2
133.1 D Aspartic acid 1.03 10.3
121.6 C Cysteine 0.94 9.4
147.1 E Glutamic acid 1.14 11.4
146.1 Q Glutamine 1.13 11.3
75.1 G Glycine 0.58 5.8
115.1 P Proline 0.89 8.9
105.1 S Serine 0.81 8.1
181.2 Y Tyrosine 1.40 14.0
174.2 R Arginine 1.35 13.5
155.2 H Histidine 1.20 12.0
131.2 I Isoleucine 1.02 10.2
131.2 L Leucine 1.02 10.2
146.2 K Lysine 1.13 11.3
149.2 M Methionine 1.16 11.6
165.2 F Phenylalanine 1.28 12.8
119.1 T Threonine 0.92 9.2
204.2 W Tryptophan 1.58 15.8
117.5 V Valine 0.91 9.1
Average ˚ Angstr¨ oms diameter per amino acid → 10.6
∗∗[14].
the matching myelin-speciﬁc non-IgE isotypes. In order
to simplify the process, the non-IgE antibody level was
determinedbymeasuringepitope-speciﬁchumankappaplus
lambdachainsandsubtractingthematchingepitope-speciﬁc
IgE. With experience, it became obvious that the speciﬁc IgE
subtractionwasunnecessaryastheIgEwasexceedinglysmall
in comparison to the matching non-IgE antibodies.
Thereafter, the evolved MS test employed the formula:
IgE/(kappa + lambda). Individual humoral epitopes were
mimicked by single peptides that were 5 amino acids in
length [4], the size that the author had previously estimated
would ﬁt into a single antibody Fab site.
When analyzing surface pentameric structures of indi-
vidual myelin proteins for potentially serving as humoral
epitopes (Section 2) and comparing each structure against
surface pentamers on all human genome proteins, it was
noted that singular, potentially MS-associated, mimotopic
peptides displayed amino acid sequences that were located
on the surface of a single, speciﬁc myelin protein and on
no other protein transcribed from the human genome.
Those unique pentamers were employed in the MS test
development.
2.MaterialsandMethods
The Hopp and Woods hydrophilicity method for locating
epitopic sites on linear protein sequences [15]w a su s e d
to predict the humoral epitopes on (a) myelin proteolipid
protein (PLP, [16]); (b) myelin oligodendrocyte glycoprotein
(MOG, [17]); (c) myelin basic protein (MBP) Isoforms
1[ 18], 2 [19]a n d3[ 20]; (d) oligodendrocyte myelin
glycoprotein [21], (e) Claudin 11 [22].
In order to estimate the functional distance (in ˚ Ang-
str¨ oms) between epitopes on the surface of each myelin pro-
tein, as depicted on its Hopp and Woods plot, the following
tasks were per formed.
(1) The average diameter of constituent amino acids was
determinedby(a)comparingthemassofeachamino8 ISRN Neurology
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Figure5:Apotentiallyfunctionaldimersitewithanintervaldistanceof95 ˚ Angstr¨ omsbetweentheepitopesVTLRIandHSYQEisillustrated.
acid relative to the mass of alanine with its known
diameter of 6.9 ˚ Angstr¨ oms [14]; (b) multiplying
individual mass ratios times 6.9 ˚ Angstr¨ oms to obtain
estimated amino acid diameter s for the non-alanine
amino acids; (c) averaging the resulting amino acid
diameters to obtain a n overall average amino acid
diameter of 10.6 ˚ Angstr¨ oms (Table 1).
(2) Individual Hopp and Woods, Excel X-Y plots of
each protein’s amino acid sequence were modiﬁedISRN Neurology 9
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Figure 6: A potentially functional dimer site with an interval distance of 56 ˚ Angstr¨ oms between the epitopes RNVRF and HSYQE is
illustrated.
so as to only depict the protein’s hydrophilic surface,
either extracellular or intracellular, as if ﬂattened by
trimming away all amino acids that were functionally
hydrophobic, and likely to be located in the protein
interior, but leaving 2 on each hydrophilic edge to
reﬂect infolding toward the protein center (Figures 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15).
(3) The bridging distance between dimeric surface epi-
topes on individual myelin proteins was estimated by
multiplying the intervening amino acids number by
10.6 ˚ Angstr¨ oms per amino acid.
(4) Because a protein surface is not ﬂat but oscillates in
depth, sera from an age- and gender-varied MS-neg-
ative control group were sequentially tested to mea-
sure dimer-point, myelin epitope-speciﬁc IgE/(kappa
+ lambda) values while reducing the estimated
dimeric distances in 5 percent intervals to ﬁnd a
reduction percentage to use as a factorial adjustment
which simulated staircase dips in normally rolling
s u r f a c ec o n t o u r so fp r o t e i n sa n dt h u sa ﬀorded func-
tionally negative test results for the controls (no
ideal dimers present). A 25% reduction of the linear10 ISRN Neurology
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Figure 7: A potentially non-functional dimer site with an interval distance of 103 ˚ Angstr¨ oms between the epitopes RNVRF and AAMEL is
illustrated.
distances attained in Step 3 between dimeric epitopes
aﬀorded test-negative results for all initially tested,
negative-control serum samples by exhibiting no
more than one dimer point as being IgE/(kappa +
lambda) test positive.
(5) In validation, when testing positive control MS
patient sera and employing the 25% reduction factor,
dimer bridging, test-positive values were attained
whose corresponding epitopes’ separation ranged
from between 40 to 100 ˚ Angstr¨ oms, thus indicating
a likelihood of mast cell degranulation. Claudin
11 and oligodendrocyte myelin glycoprotein lacked
IgE dimer bridging sites and were, therefore, not
analyzed further. Pathological dimer bridging values
and locations are depicted in Figures 4–9 for MOG
and Figures 10–15 for MBP.
A similar contour-mapping approach was not used for
PLP because it has but one structurally unique epitope
expressed on the myelin surface, ADARM (Figures 1, 2,
3). However, PLP molecules are highly prevalent on myelin
and correctly spaced (65–71 ˚ Angstr¨ oms) between monomersISRN Neurology 11
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Figure 8: A potentially functional dimer site with an interval distance of 95 ˚ Angstr¨ oms between the intracellular MOG epitopes IENLH and
KTGQF is illustrated. The epitopes’ complexing with speciﬁc IgE antibodies and mast cells likely hinges upon disruption of the overhanging
oligodendrocyte membrane surface.
[23] so as to serve as ideal IgE dimer-binding sites, notwith-
standing allowance for the 25% rolling contour adjustment.
In Figure 1, Proteolipid protein Isoform 1 (PLP1) is
displayed as a Hopp and Woods XY plot with eleven vertical
columns. The leftmost column depicts the amino acid
sequence number of the protein chain. The second column
from the left lists the sequential, corresponding amino acids.
The sixth, left-most, column displays the hydrophilic index
(HI) of each listed amino acid. The tenth column from
the left depicts the sum-of-seven, continuous amino acids,
hydrophilicindexvalueofeachaminoacidderivedbyadding
to its hydrophilic index (HI) the indices of the 3 amino acids
that precede it plus the indices of the three amino acids that
follow it. Areas that are net hydrophilic (yellow highlighted)
are apt to be on the protein surface while those that are net
hydrophobic (uncolored) would be on the protein edge or
imbedded within the protein center. The protein surface can
either be extracellular or intracellular.
MOG has been shown to be diﬀerentially expressed in
various isoforms. However, for the purpose of identifying
the potential array of MOG humoral epitopes possible on
all isoforms and the epitopes’ utility in dimer formation,
analysis of MOG Sanger Institute Isomer 1 (Figures 4–
9)p r o v e ds u ﬃcient. The analysis illustrated the presence
of two potential disease-functional dimer sites on the
oligodendrocyte, extracellular MOG portion (Figures 5 and
6) and two potential subsurface, intracellular dimer sites
(Figures 8 and 9) if the latter were somehow immuno-
surveillance exposed by myelin surface (oligodendrocyte
surface) disruption. By experience, accurate representation12 ISRN Neurology
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Figure 9: Illustrated are three potentially functional dimer sites with interval distances of 80, 71, and 64 ˚ Angstr¨ oms between the interlayer
MOG epitopes NLHRT and KTGQF, LHRTF and KTGQF, and HRTFE and KTGQF. Dimeric IgE complexing hinges upon disruption of the
overhanging oligodendrocyte membrane surface and facilitated intracellular antibody inﬂow. For serum antibody immunoassay purposes,
the longer, inclusive peptide NLHRTFE can be used together with KTGQF as both peptides are suﬃciently hydrophilic when coupled with
the peptide-solubilizing, amino-ADOOA-ADOOA linker.
of an antibody binding site mandated exhibiting a unique
pentamer ﬂanked by an amino acid on each side.
Myelin basic protein, an oligodendrocyte intracellular
protein also potentially accessible by myelin surface dis-
ruption, exhibits a more complex array of potentially tar
getable epitopes and dimer conditions than PLP or MOG.
All potential dimer sites are exhibited by a combination of
myelin basic protein Isoform 1 (Figures 10–12), Isoform
2 (Figures 13-14), and Isoform 3 (Figure 15). For epitope-
mapping, singularly unique protein surface regions longer
than 5 amino acids were subdivided into overlapping
pentamers to represent all possible-single-antibody binding
sites (i.e., Figure 10).
2.1. Microtiter Test Plate Layout. As depicted in Figure 16,
the basic MS test plate contained 14 mimotopic peptides
corresponding to the myelin epitopes illustrated in Fig-
ures 1 through 15.E a c hp e p t i d ec o n s t r u c t( M i m o t o p e s
Pty, Clayton, Australia) applied to the microplate wells
comprised a mimotopic peptide preceded by an ami-
nated hydrophilic linker, 8-amino-3,6-dioxaoctanoic acid2
(amino-ADOOA-ADOOA). The epsilon amino group on
peptidelysineresidueswasblockedwitha(4,4-dimethyl-2,6-
dioxocyclohex-1-ylidene)-3-methylbutyl (ivDde) group, to
prevent undesirable, lateral binding when attaching peptide
constructs to test plate wells via their free amide groups.ISRN Neurology 13
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Figure 10: Seven structurally unique epitopes located on the outer surface of myelin basic protein (MBP) Isoform 1 are illustrated. The
dimer group 1 combinations encompass the overlapping, epitopic pentamers DNEVF, NEVFG, EVFGE, and VFGEA coupled to QDTAV.
The dimer group 2 combinations encompass the pentamers DNEVF, NEVFG, EVFGE, and VFGEA coupled to DTAVT. The dimer group 3
combinations encompass the overlapping, epitopic pentamers QDTAV and DTAVT individually coupled to PKNAW. Dimer group 1 displays
epitope intervals that are 95, 87, 80, and 72 ˚ Angstr¨ oms. Dimer group 2 displays epitope intervals that are 88, 80, 72, and 64 ˚ Angstr¨ oms.
Dimer group 3 displays epitope intervals that are 48 and 40 ˚ Angstr¨ oms. Dimeric IgE complexing hinges upon disruption of the overhanging
oligodendrocytemembranesurfaceandfacilitatedintracellularautoantibodyinﬂow.Forserumantibodyimmunoassaypurposes,thelonger,
inclusive peptide DNEVFGEA can be used together with QDTAVT and QDTAVT used together with PKNAW as all three peptides are
suﬃciently hydrophilic when coupled with the peptide-solubilizing construct, amino-ADOOA-ADOOA linker.14 ISRN Neurology
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Figure 11: A second set of potentially functional intracellular dimer sites on are displayed on MBP Isoform 1. The inclusive epitope
pairs are: DNTFK, LQTIQ and DNTFK, QTIQE and NTFKD, LQTIQ and NTFKD, QTIQE with respective interval distances of 40 and
48 ˚ Angstr¨ oms. Dimeric IgE complexing hinges upon disruption of the overhanging oligodendrocyte membrane surface and facilitated
intracellular autoantibody inﬂow. For serum antibody immunoassay purposes, the longer, inclusive peptide DNTFKD can be used together
with LQTIQE as both peptides are suﬃciently hydrophilic when coupled with the peptide-solubilizing, amino-ADOOA-ADOOA linker.
2.2. Peptide Constructs Formulation. Each construct was dis-
solved in pH 7.2 phosphate buﬀered saline (PBS) immo-
bilization buﬀer (Product no. 28372, Thermo Scientiﬁc,
Rockford, IL, USA), at an assay optimum concentration
(Table 2).
2.3. Peptide Constructs Application. 100μLo fe a c hp e p t i d e
construct solution was applied in quadruplicate to 96-
well, amide-binding, maleic anhydride-activated, white 96-
well plates (Thermo Scientiﬁc, Product no. 15108). Four
wells were left blank for plate background determination.
The plates were covered with acetate plate sealers (Thermo
Scientiﬁc, Product no. 3501) and the construct solutions
incubated at 21−26 degrees C for 18−24hrs.
2.4. Plate Blocking Procedure. 120μLo fH S Ab a c k g r o u n d
blocking solution (10mg recombinant human serum albu-
min per mL immobilization buﬀer) was applied per well.
The construct/blocking solutions were incubated at 21–26
degrees C for 18–24hrs and plates aspirated and dried.
2.5. Lysine Deprotection Procedure. 200μLo fa2 %s o l u t i o n
of hydrazine monohydrate (Sigma Chemical Company, St.
Louis, MO, Product no. 207942) in DMSO (dimethyl sulfox-
ide, Thermo Scientiﬁc Product No. 20688) was applied per
well and incubated at 21–26 degrees C for 10 minutes. The
hydrazine solution was aspirated and the procedure repeated
two additional times. 250μL of phosphate buﬀered saline
with 0.05% Tween-20 (PBST, Thermo Scientiﬁc Product no.
28320) was applied per well. Plates were incubated at 21–26ISRN Neurology 15
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Figure 12: A third set of potentially functional intracellular dimer sites on MBP Isoform 1 is displayed incorporating the epitopes KDSHH,
DSHHP, and SHHPA individually coupled to HGRTQ. The dimer epitopes’ complexing with speciﬁc IgE antibodies likely hinges upon
disruption of the overhanging myelin surface and speciﬁc antibody inﬂow. For serum antibody immunoassay purposes, the longer, inclusive
peptide KDSHHPA can be used together with HGRTQ as both solubilize readily with the amino-ADOOA-ADOOA linker.
degrees C for 30 minutes, aspirated, washed three additional
times, aspirated, and dried.
2.6. Microplate Storage. After drying at 21−26 degrees C
for 18−24hrs in a clean, covered container, test plates were
sealed with acetate plate sealers and stored at room temp-
erature until needed. Individual plates were used for both
speciﬁc IgE and speciﬁc (kappa + lambda) assays.
The speciﬁc IgE immunoassay entailed use of 100 uL/well
of neat subject serum that had been spiked with 1mg/mL
aminated hydrophilic linker solution to neutralize poten-
tial, antilinker antibodies (50μL linker solution per 12mL
serum). Plates were sealed and incubated for 2 hours at
21–26 degrees C and then washed four times with PBST
(250μL/well followed by immediate aspiration). 100μLo f
4μg/mL biotinylated, goat anti-human IgE was applied per
well. (The anti-IgE solution comprised 96μLo fV e c t o rL a b s ,
Burlingame, CA, Product no. BA-3040 added to 11.9mL
of conjugate diluent (10mg/mL recombinant HSA in PBST
+0.25% PEG 4000)). After incubation for 2 hours at 21–
26 degrees C, the plates were washed and 100 uL/well
of 64ng/mL streptavidin horseradish peroxidase (Thermo
Scientiﬁc Product No. 21126 diluted in HSA conjugate
diluent) applied. Test plates were incubated for 30 minutes
at 21−26 degrees C and then washed. 100uL/well of Thermo
ScientiﬁcChemiluminescencesubstrate(ProductNo.37074)
was applied and the plate(s) read 1−3m i n u t es after appli-
cation using a Luminoskan Ascent Microplate Luminometer
(Thermo Scientiﬁc, Waltham, MA, USA).
2.7. Speciﬁc (Kappa + Lambda) Test Portion. The linker-
spiked test serum sample used in the speciﬁc IgE assay
was diluted 1/25,000 by (a) making a 1/100 dilution
mixing together 100μL linker-spiked serum and 9.9mL16 ISRN Neurology
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Figure 13: Potentially functional dimer sites on MBP Isoform 2 and conditions match the dimersets on MBP Isoform 1 displayed in
Figure 10.
PBST and (b) spiking 11.950 HSA conjugate diluent with
48μL of the 1/100 diluted serum. Plates were ﬁlled with
100μL/well of 1/25k diluted serum, sealed, and incubated
for 2 hours at 21–26 degrees C. Equal volumes of Vector
biotinylated, goat anti-human kappa antibody (BA-3060)
plus biotinylated, goat anti-human lambda antibody (BA-
3070) were mixed together to form a 50:50 biotinylated
anti-(kappa + lambda) concentrate (500μg/mL). 96μLo f
the anti-(kappa + lambda) concentrate was mixed with
11.9mL of HSA conjugate diluent and 100μL of the
resulting solution applied per well. After 2-hour incuba-
tion at 21–26 degrees C, plates were washed and 100uL
per well of 16ng/mL streptavidin horseradish peroxi-
dase solution applied. Test plates were incubated at 21–
26 degrees C for 30 minutes, aspirated, and washed.
100uL/well of Thermo Scientiﬁc chemiluminescence sub-
strate was applied and the plates read at 1–3 minutes after
application.
2.8. Individual IgE/(Kappa + Lambda) Determinations. Spe-
ciﬁc IgE and matching speciﬁc (kappa + lambda) signals
were obtained by reading corresponding, matched test plates
on the microplate luminometer. Average test values corre-
spondingtoindividualmimotopicpeptidesweredetermined
by discarding the highest and lowest of four values and
averaging the remaining two. The same procedure was
followed for the four background well values, together with
calculation of twice the standard deviation of the two-
point average. The blank well background was deemed to
be its average value plus twice the standard deviation. The
plate blank well value was subtracted from each peptide-
coated well average to yield a net signal. Kappa + lambda
values were multiplied by 25,000 in order to delineate
the corresponding neat serum (undiluted) epitope-speciﬁc
kappa + lambda antibody levels. IgE/(K+L) values were
multiplied by 1,000,000 in order to bring each quotient to
a positive number if attainable. Test results with negativeISRN Neurology 17
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Figure 14: Potentially functional dimer sites and conditions on MBP Isoform 2 match a dimer set on MBP Isoform 1 as displayed in
Figure 11.
values or values of less than 0.5 were assumed to be test
negative.
2.9. Serum Sample Selection. Disease-positive and disease-
negative (control) sera were purchased from BioServe
(Beltsville, MD, USA). Multiple sclerosis-positive samples
were from patients who had not yet received MS-speciﬁc
therapy, patients who were taking interferon and/or Copax-
one (glatiramer acetate) with or without medication shown
to be immunosuppressive (Tables 3(a)–3(e)), and patients
who were only being treated with immunosuppressive
substances.
3. Results
3.1. Control Subjects. As depicted in Figures 17 and 18,
neither female (n = 10) nor male (n = 10) age-varied,
control serum samples were MS test positive by exhibiting
IgE/(kappa + lambda) dimer-positive results. Being positive,
the control sera would have been IgE/(kappa + lambda)
positive when tested against the PLP ADARM peptide
antigen (Figures 1–3) and/or the non-PLP peptides listed on
the left-most column of Table 4 that were properly dimer
paired. The proper pairings are depicted on Figures 5-6 and
Figures 8–15.
3.2. Untreated MS Patients. Five MS patients who had not
taken Copaxone, beta interferons, or immunosuppressive
agents were MS test positive (Figure 19) .A l lw e r eI g E
dimer positive against PLP. Three of ﬁve patients were also
MOG dimer-positive. Of the latter group, all three were
myelin surface positive and two patients were also positive
against subsurface MOG epitopes (positives are highlighted
in yellow). None were MBP dimer positive.
3.3. Patients Taking Copaxone or Interferon Only (Figure 20).
All three patients were dimer positive against the sole PLP18 ISRN Neurology
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Figure 15: Potentially functional intracellular dimer sites and conditions on MBP Isoform 3 which are similar to the third dimer set on MBP
Isoform 1 as displayed in Figure 12.
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Figure 16: MS test microplate layout of mimotopic peptide antigens covalently coupled to individual test wells. The test plate format was
employed for both speciﬁc IgE and non-IgE serum antibody determinations.ISRN Neurology 19
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Figure 17: MS test results for ten female control serum samples, ages 20–66, are displayed. Tested samples were from Caucasian and African-
American donors who did not have multiple sclerosis. Speciﬁc IgE/(kappa + lambda)-positive results are conﬁned to single, nondimer
participating epitope.
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Figure 18: MS test results for ten male control serum samples, ages 20–66, are displayed. Tested samples were from Caucasian and African-
American donors who did not have multiple sclerosis. Speciﬁc IgE/(kappa + lambda)-positive results are conﬁned to single, non-dimer
participating epitope.
epitope, ADARM, irrespective of whether each had relapsing
remitting (RR), secondary progressive (SP), or primary
progressive (PP) MS. Individual test scores were lower than
scores for the untreated MS group. None was IgE dimer
positive against MOG or MBP.
3.4. Patients Taking Interferon + Immunosuppressive Agents
(Figure 21). One of twelve patients was PLP dimer test
positive. None were positive against MOG or MBP. (Poten-
tially immunosuppressive, ancillary agents are numerically
identiﬁedinyellowatthebottomoftheﬁgureandreferenced
in Table 3.)
3.5. Patients Only Taking Immunosuppressive Agents
(Figure 22). Four of fourteen test subjects were PLP
IgE dimer test positive, irrespective of disease classiﬁcation.
None was IgE dimer positive against MOG or MBP.
(Immunosuppressive agents are identiﬁed in yellow at the
bottom of the ﬁgure and referenced in Table 3.)
3.6. Patients Taking Copaxone plus Immunosuppressive
Agents (Figure 23). Only one of six patients was PLP and
MOG dimer test positive. None was MBP dimer positive.
(Immunosuppressive agents are identiﬁed in yellow at the
bottom of the ﬁgure and referenced in Table 3.)20 ISRN Neurology
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Figure 19: MS test results for serum samples obtained from multiple sclerosis patients (4 Caucasians and 1 African American) who had
not yet received pharmacotherapy. Individual epitope- positive results are highlighted with yellow plus signs. To be dimer test positive, MS
patients had to be ADARM-speciﬁc, IgE/(kappa + lambda)-positive and/or IgE/(kappa + lambda)-positive for the dimer pairs HSYQE and
VTLRI, HSYQE and RNVRF, IENLH and KTGQF, and/or NLHRTFE and KTGQF.
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Figure 20: MS test results for serum samples obtained from multiple sclerosis patients only treated with interferon or Copaxone. Individual
epitope-positive results (all against the PLP epitope ADARM) are highlighted with a yellow plus sign. Being test-positive to PLP indicates
dimer-positivepresencebecauseofthePLPmonomers’highmyelinsurfaceprevalenceandadequateintermolecularmonomer-to-monomer
separation (65–71 ˚ Angstr¨ oms).ISRN Neurology 21
Table 2: Concentrations of mimotopic peptide constructs used in application to individual microplate test wells are listed alongside each
construct sequence. The basic procedure is described in Section 2.
Microgram of mimotopic peptide construct per milliliter of coating buﬀer for MS test microplate wells
Peptide amino Acid Sequence of
amino-ADOOA-ADOOA-peptide Construct
ADOOA-peptide construct
Peptide Construct μg/mL
Concentration
Construct molar mass
(kilodaltons)
(1) ADARM 0.26 0.56
(2) HSYQE 0.31 0.66
(3) RNVRF 0.33 0.69
(4) VTLRI 0.28 0.6
(5) IENLH 0.29 0.62
(6) NLHRTFFE 0.5 1.06
(7) KTGQF 0.27 0.58
(8) DNTFKD 0.39 0.82
(9) HGRTQ 0.28 0.6
(10) LQTIQE 0.34 0.73
(11) PKNAW 0.34 0.73
(12) QDTAVT 0.3 0.63
(13) YKDSHHPA 0.45 0.95
(14) DNEVFGEA 0.5 0.9
Age: 15 19 47 58 22 45 68 37 50 34 43 52
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Figure 21: MS test results for serum samples obtained from multiple sclerosis patients treated with interferon plus psychotropic
pharmaceuticals and/or other potentially immunosuppressive agents. Individual dimer-positive results (just one) are highlighted with a
yellow plus sign. The immunosuppressive substances are identiﬁed by yellow-highlighted numbers at the bottom of columnar, individual
patient test results and referenced in literary citations provided in Table 3 that are listed at the end of the paper.22 ISRN Neurology
Table 3: Psychotropic pharmaceuticals and other agents shown to be immunosuppressive are listed (left column) alongside their speciﬁc
suppressive eﬀects (middle column) and describing literary citations (right column). Speciﬁc citations are listed in the References section.
Anti-inﬂammatory Agent (ID no. marked
yellow on individual plots) Immunosuppressive eﬀect References
(1) Mesalazine Potent and speciﬁc inhibitor of nuclear factor kappa B. [24]
Anticonvulsants
(2) Dilantin (phenytoin sodium) Humoral immune suppressant [25]
(3) Zonisamide Suppression of IFN-gamma Production by Lymphocytes. [26]
Atypical Antipsychotics
(4) Olanzapine (Zyprexa, etc.) Suppress tumor necrosis factor, (TNF)-alpha, interleukin (IL)-6, and
upregulates IL-10 [27]
Benzodiazepines:
(5) Alprazolam ( Xanax) Inhibits proliferative responses of both B- and T-cells [28]
(6) Clonazepam Depression of cellular and humoral immune response. [29]
(7) Diltiazem Induces direct immunosuppression. [30].
(8) Diazepam (Valium) Markedly suppresses Antigen-speciﬁc antibody production and T-cell
reactivity. [31]
Colesterol Lowering Drugs
(9) Atorvastatin (Lipitor) Increases in IL-10 production.
IL-10 mediates immune suppression. [32]
(10) Fenoﬁbrate (reduces
lipoproteins) A Peroxisome proliferator-activated receptor alpha agonist. [33]
(11) Pravastatin B, lymphocyte and T lymphocyte suppression. [34]
(12) Rosuvastatin (Crestor) Posttranscriptional level of genetic expression of inﬂammatory process. [35]
(13) Simvastatin (Zocor) Mediates induction of Foxp3(+)
T Cells Which Mediate Immuno-Suppression. [36]
Dopamine Reuptake Inhibitors
(Antidepressants)
(14) Bupropion (Wellbutrin, etc.) Involved in inhibiting neuroimmunomodulation. [37]
Serotonin—Norepinephrine Reuptake
Inhibitors (SNRIs, Antidepressants):
(15) Venlafaxine Suppresses proinﬂammatory cytokines [38]
Selective Serotonin Reuptake Inhibitors
(SSRIs, antidepressants):
(16) Paroxetine (trade names:
Seroxat, Paxil)
Inhibits splenocyte viability. [39]
Decreases CD4 T-helper cells. [40]
(17) Fluoxetine (Prozac) Decreases T Lymphocyte Activity. [41]
(18) Sertraline hydrochloride (Zoloft) Suppression of antigen-speciﬁc T(H)1 responses. Inhibition of
interferon gamma and stimulation of interleukin-10. [42]
(19) Clomipramine As per sertraline. [43]
(20) Trazodone (Desryl, Oleptro,
Beneﬁcat, Deprax, Desirel,
Molipaxin, Thombran, Trittico,
Mesyrel).
As per sertaline. [43]
Other Immunnosuppressants (1):
(21) Amantadine Inhibits antigen-speciﬁc T- and NK-Cell Responses. [44]
(22) Amitriptyline (Elavil, Tryptizol,
Laroxyl, Sarotex) Decrease in the Proliferation of Slenocytes and in NK Activity. [45]
(23) Clonidine (a direct-acting α2
adrenergic agonist).
Stimulates production of IL-10 (an anti-Inﬂammatory cytokine that
reduces serum antibody production.) [46]
(24) Depakote (Valproate semisodium
used to treat major depressive
disorder.)
Suppresses IL-6- and/or IL-6R-related mechanisms. [42]
(25) Donepezil (Aricept) Reversible Acetylcholinesterase Inhibitor. Suppresses
Neuroinﬂammation of the Brain. [47]
(26) Mitoxantrone (Novantrone) Chemotherapeutic agent, depletes B cells. [48]ISRN Neurology 23
Table 3: Continued.
Anti-inﬂammatory Agent (ID no. marked
yellow on individual plots) Immunosuppressive eﬀect References
(27) Levoxyl (Levothyroxine,
Synthroid). Inhibits cytokine production in T cells. [49]
(28) Warfarin (Coumadin) Suppresses IL-6 secretion.
Serves as immunosuppressant. [50]
Other Immunnosuppressants (2):
(29) Heroin and Methadone. Suppression of Cellular and Humoral Immunity. [51]
(30) Morphine. Suppression of Cellular and Humoral Immunity. [51]
(31) Oxycodone & Propoxyphene Suppression of Cellular and Humoral Immunity. [51]
(32) Prednisone Catabolic Steroid.
Suppression of Cellular and Humoral Immunity.
4. Discussion
T h et e s td a t ai sb o t ha na ﬃrmation and a signiﬁcant
challenge to the theories and work of other investigators.
It aﬃrms the premise that MS is a humoral autoimmune
disease as validated by clinicians who have worked with
Natalizumab (Tysabri), a humanized monoclonal antibody
whose therapeutic use results in a systemic increase in B
lymphocytes and, ultimately, plasma cells and speciﬁc serum
autoantibodies [52–54]. Where it diﬀe r si si na ﬀording a
precise explanation of the multilayered humoral MS process
and how it might be remedied.
We have concluded that multiple sclerosis is a com-
plex, humoral autoimmune disease caused by IgE dimer
formation on the surface or immediate subsurface of CNS
myelin that results in focal mast cell degranulation. The
degranulating mast cells likely release proteolytic enzymes
and possibly other factors that damage or destroy proximal
neurons.
Test results of MS patients taking medication shown to
haveanimmunosuppressiveeﬀectsuggesteitherinterference
with the IgE/competing antibody pathological process or
with the MS test itself. This was inferred by the quantitative
diﬀerence in MS test scores between the patients who were
taking no medication and exhibited relatively high test
scores, patients who were being treated with a single MS-
speciﬁc pharmaceutical (beta interferon or Copaxone), but
had relatively low positive test scores, and patients who were
taking the described immunosuppressive agents, with or
without interferon or Copaxone, and were only sporadically
MS test positive.
This suggests that the conventional, multiple therapy
approach may potentially hinder therapeutic eﬃcacy by
altering normal immune function.
As interferon and Copaxone are prescribed because of
theirMS-speciﬁc,immunosuppressive,eﬀectandMSislikely
an autoimmune disease, it is reasonable to expect some
decrease in humoral immune function among speciﬁcally
treated patients, as reﬂected by the low anti-PLP test scores
exhibited in Figure 20. However, the test scores of MS
patients who were also receiving ancillary substances that
have been shown to be immunosuppressive (Figures 21–
23), infer that augmentation of immune suppression may
not always be therapeutically beneﬁcial. Another possibility
is that the MS-speciﬁc and ancillary pharmaceuticals may
also hinder serum immunoassay function making some or
all speciﬁc immunoassays diagnostically unreliable.
Also suggested is the possibility that (1) the ancillary
medications, having only been in use since the early twen-
tieth century, may have historically played an instigating or
promoting role in MS causation and/or progression through
disruption of homeostatic, immune system controls.
The absence of MS test-positive results against MBP
dimers may have been due to their deep, intracellular
location and relative freedom from immune surveillance and
pathological action. It may also indicate that (a) successful
MBP humoral targeting ﬁrst calls for myelin surface disrup-
tion via action against PLP and/or outer MOG in order to
provide penetrating access for anti-MBP antibodies and/or
lymphocytes; (b) MBP is an autoimmune target, but of lesser
frequency or importance than the epitopes on the outer
surface or immediate sub-surface of myelin.
IfMSprovestobeanIgEdimer-driven,humoralautoim-
mune disease, as is suggested by the test data, treatment
with mimotopic peptides homologous to those used in the
diagnostic immunoassay might prove to be therapeutically
beneﬁcial by neutralizing anti-myelin IgE antibodies. The
therapeuticpeptideswouldneedtobeadministeredinsucha
way as to insure intravascular delivery of quantities suﬃcient
to neutralize all epitope-speciﬁc dimeric IgE autoantibodies
through antibody-to-peptide complexing or by neutralizing
key epitope-speciﬁc IgE antibodies whose target epitopes
are cornerstones of a number of pathological dimers. The
elimination of one or two dimer-point-speciﬁc autoantibod-
ies could prevent multi-site-initiated mast cell degranulation
and halt the pathological autoimmune process.
Cornerstone dimer-blocking peptides are highlighted in
bold within the full array of potentially therapeutic peptides
listed in the sixth column from the left of Table 4 and whose
corresponding epitopes and dimers are illustrated in Figures
4 thru 15.
To be eﬀective, therapeutic peptides would need to (a)
possess an exact structural match with the speciﬁc myelin
protein epitope; (b) be of suﬃcient length (5-6 amino acids)
to easily ﬁt and be avidly bound by a single autoantibody;24 ISRN Neurology
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Figure 22: MS test results for serum samples obtained from multiple sclerosis patients only treated with psychotropic pharmaceuticals or
other immunosuppressive agents. Individual epitope-positive test results (4 ADARM positives) are highlighted with a yellow plus sign. The
immunosuppressive substances are identiﬁed by yellow-highlighted numbers at the bottom of the columnar, individual patient test results
and referenced in literary citations provided in Table 3 that are listed at the end of the paper.
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Figure 23: MS test results for serum samples obtained from multiple sclerosis patients treated with Copaxone plus psychotropic
pharmaceuticals or other immunosuppressive agents. Individual epitope-positive results (just one tested individual) are highlighted with
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Table 4: Listed are structurally unique, mimotopic, peptides serving as diagnostic and therapeutic antigens. Respective peptide hydrophilic
indices (HIs) are displayed in columns 5 and 7. Peptides used for initial diagnosis can be of maximum, unique length (column 4) or
fractionated into pentameric (single epitope) equivalents (column 6). Either takes place. Each test peptide is synthesized with an amino-
ADOOA-ADOOA linker. The amide group is used for covalent coupling to microplate wells, and the ADOO A-ADOOA construct, being
very hydrophilic, solubilizes all peptides, especially those that are hydrophobic. The selected myelin dimer-cornerstone, peptide homologues
for therapy are therapeutically promising because of their in vivo (a) net hydrophilicity for good solubility; (b) relatively small size for
intravascular permeation; and (c) ability to simultaneously abrogate formation of up to 20 pathological myelin dimers by administering just
4 pentameric plus 2 hexameric peptides (bold highlighted in columns 4 and 6) in lieu of needing to employ up to 28 individual therapeutic
pentamers and having to confront individual solubility issues, and so forth.
MS-speciﬁc peptides sequences for diagnosis and therapy
Myelin protein Full-length mimotopic
peptides HI Constituent, single-epitope,
pentameric equivalents HI
PLP m.s. ADARM 3.7 ADARM 3.7
MOG m.s. HSYQE 0.7 HSYQE 0.7
RNVRF 2.2 RNVRF 2.2
VTLRI −2.5 VTLRI −2.5
MOG i.c. IENLH −0.9 IENLH −0.9
NLHRTFE 1 NLHRT 0.5
LHRTF −2.2
HRTFE 2.6
KTGQF 0.3 KTGQF 0.3
MBP i.c. Isoforms 1,2 DNEVFGEA 4.7 DNEVF 2.2
”N E V F G 2 . 0
”E V F G E 2 . 0
”V F G E A −1.5
Isoforms 1,2 QDTAVT 0.4 QDTAV 0.8
” DTAVT 0.2
Isoforms 1,2 PKNAW −1P K N A W−1
MBP i.c. Isoforms 1,2 DNTFKD 6.3 DNTFK 3.3
” NTFKD 3.3
Isoforms 1,2 LQTIQE −1 LQTIQ -3.6
” QTIQE 1.2
MBP i.c. Isoform 1 KDSHHPA 3 KDSHH 5.3
” DSHHP 2.3
” SHHPA −1.2
Isoforms 1,3 HGRTQ 2.3 HGRTQ 2.3
MBP i.c. Isoforms 3 YKDSHHPA 2.5 YKDSH 2.5
KDSHH 5.3
DSHHP 2.3
SHHPA −1.2
Bold: cornerstone epitopes.
(c) be relatively hydrophilic so as to be functionally soluble
when injected or ingested; (d) if ingested, be aided in enteric
absorption by pharmaceutical agents such as medium-chain
fatty acid constructs [55], superporous hydrogels [56], or N-
trimethyl chitosan chloride [57].
5. Summary
Evidence is presented that multiple sclerosis is a humoral
autoimmune disease caused by IgE dimer formation on the
surface or immediate subsurface of CNS myelin that results26 ISRN Neurology
in focal mast cell degranulation with release of tissue-
damaging enzymes and/or other substances.
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